News
Kivo Health Secures $10M Series A for Virtual Chronic Disease Care
FundingOctober 28, 2026, 9:35 pm
Kivo Health secured $10 million in Series A funding, led by Allumia Ventures. This investment accelerates its AI-powered virtual care platform. The company targets seniors managing chronic diseases, initially focusing on Chronic Obstructive Pulmonary Disease (COPD). Kivo offers a fully virtual pulmonary rehabilitation program, delivered directly into patients' homes. This innovative model addresses significant access barriers to traditional care. It demonstrates substantial improvements in patient symptoms, functional capacity, and mood. The platform also drastically reduces hospitalizations, emergency room visits, and overall healthcare spending. Kivo aims for national expansion, bolstering health plan partnerships and clinical operations. Future plans include applying its successful model to additional high-cost chronic conditions affecting the senior population. This move marks a pivotal moment for digital health solutions in senior care, promising more accessible, effective, and cost-efficient chronic disease management across the nation.
Kivo Health, a Seattle-based innovator, just closed an oversubscribed $10 million Series A funding round. Allumia Ventures led the investment. Corewell Health Ventures, Y Combinator, Heuristic Capital, and MassMutual Ventures also participated. This round brings Kivo’s total funding to over $16 million. The capital fuels national expansion. It advances Kivo’s AI-powered virtual care platform. This move transforms chronic disease management for seniors.
Kivo Health targets a critical gap in elder care. Millions of seniors grapple with chronic conditions. Traditional healthcare often falls short. Kivo brings proactive, high-quality care directly home. Its platform merges cutting-edge AI with expert clinical support. This partnership ensures personalized, accessible treatment.
The company initially concentrates on Chronic Obstructive Pulmonary Disease (COPD). COPD affects up to thirty million Americans. It causes significant suffering and high healthcare costs. Traditional pulmonary rehabilitation offers proven benefits. Yet, its utilization remains alarmingly low. Only 2.7% of eligible patients receive it after hospitalization. Limited in-person clinic capacity creates a major barrier. Many seniors struggle with transport or mobility. Kivo directly addresses these systemic failures.
Kivo’s flagship offering is a fully virtual pulmonary rehabilitation program. This program delivers comprehensive care into patients' homes. It removes access obstacles. Patients receive a dedicated, cellular-connected tablet. The kit includes resistance exercise bands and a Bluetooth pulse oximeter. This turnkey hardware fulfillment simplifies technology access for seniors. No complex Wi-Fi setup is needed.
The program features a front-loaded clinical intensity phase. Patients begin with two months of intensive support. Bi-weekly live video appointments connect them with licensed respiratory therapists and exercise physiologists. Clinicians guide structured aerobic and strength conditioning. They monitor continuous pulse oximetry. Inhaler administration techniques are validated. Early symptom recognition protocols are taught. This hands-on approach ensures engagement and understanding.
Following this intensive period, patients transition. They enter a longitudinal maintenance phase. Monthly monitoring visits continue for at least eight months. This establishes a year-long clinical safety net. It intercepts acute flare-ups. This proactive monitoring prevents hospitalizations. Kivo employs its core clinical team directly. Respiratory therapists and exercise physiologists are W-2 employees. Pulmonologists operate through a hybrid model. This ensures consistent, high-quality care.
Kivo’s virtual program yields impressive results. A peer-reviewed study confirmed significant improvements. Patients saw a 24% improvement in symptoms. Functional capacity improved by 34%. Mood saw a 25% improvement. Program attendance was consistently high, at a median of 83%. These numbers demonstrate strong patient engagement and efficacy.
Beyond clinical outcomes, Kivo offers substantial economic benefits. An independent actuarial analysis estimates significant savings. Kivo’s approach can reduce total healthcare spending by $8,245 per patient annually. This comes from fewer hospitalizations. It includes reduced emergency room visits. Fewer nursing home days also contribute. Preventing a single COPD hospitalization, for instance, saves over $19,000.
Kivo’s commercial growth strategy leverages diverse channels. It secures robust health plan partnerships. UnitedHealthcare, Humana, Blue Cross, Aetna, Priority Health, Medicare, and Medicaid cover Kivo’s programs. This broad coverage ensures wide patient access.
Strategic health system partnerships also drive growth. Under a fee-for-service model, hospitals refer post-discharge COPD patients. Kivo’s virtual clinic extends health systems' capacity. It helps reduce 30-day COPD readmission penalties. The Hospital Readmissions Reduction Program (HRRP) imposes these penalties. Health systems also capture downstream remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) billing codes.
In parallel, Kivo scales value-based arrangements. It partners directly with Medicare Advantage organizations and accountable care organizations (ACOs). By preventing avoidable events, Kivo generates medical cost offsets. This allows participation in shared savings. It aligns with risk-adjusted capitation benchmarks. This strategy supports long-term financial sustainability and impact.
The new financing will fuel Kivo’s ambitious plans. The company will expand health plan partnerships. Clinical operations will grow nationally. Further advancements to the AI platform are underway. Kivo plans to apply its successful model to other high-cost chronic diseases. These conditions also heavily impact seniors. This expansion promises a future where advanced, accessible virtual care becomes standard. Kivo Health is truly pioneering the next generation of digital health solutions for an aging population.
Kivo Health Secures $10M Series A for Virtual Chronic Disease Care
Kivo Health, a Seattle-based innovator, just closed an oversubscribed $10 million Series A funding round. Allumia Ventures led the investment. Corewell Health Ventures, Y Combinator, Heuristic Capital, and MassMutual Ventures also participated. This round brings Kivo’s total funding to over $16 million. The capital fuels national expansion. It advances Kivo’s AI-powered virtual care platform. This move transforms chronic disease management for seniors.
Reinventing Senior Chronic Care
Kivo Health targets a critical gap in elder care. Millions of seniors grapple with chronic conditions. Traditional healthcare often falls short. Kivo brings proactive, high-quality care directly home. Its platform merges cutting-edge AI with expert clinical support. This partnership ensures personalized, accessible treatment.
Focus on COPD: A National Health Challenge
The company initially concentrates on Chronic Obstructive Pulmonary Disease (COPD). COPD affects up to thirty million Americans. It causes significant suffering and high healthcare costs. Traditional pulmonary rehabilitation offers proven benefits. Yet, its utilization remains alarmingly low. Only 2.7% of eligible patients receive it after hospitalization. Limited in-person clinic capacity creates a major barrier. Many seniors struggle with transport or mobility. Kivo directly addresses these systemic failures.
The Virtual Pulmonary Rehabilitation Breakthrough
Kivo’s flagship offering is a fully virtual pulmonary rehabilitation program. This program delivers comprehensive care into patients' homes. It removes access obstacles. Patients receive a dedicated, cellular-connected tablet. The kit includes resistance exercise bands and a Bluetooth pulse oximeter. This turnkey hardware fulfillment simplifies technology access for seniors. No complex Wi-Fi setup is needed.
A Structured Path to Better Health
The program features a front-loaded clinical intensity phase. Patients begin with two months of intensive support. Bi-weekly live video appointments connect them with licensed respiratory therapists and exercise physiologists. Clinicians guide structured aerobic and strength conditioning. They monitor continuous pulse oximetry. Inhaler administration techniques are validated. Early symptom recognition protocols are taught. This hands-on approach ensures engagement and understanding.
Following this intensive period, patients transition. They enter a longitudinal maintenance phase. Monthly monitoring visits continue for at least eight months. This establishes a year-long clinical safety net. It intercepts acute flare-ups. This proactive monitoring prevents hospitalizations. Kivo employs its core clinical team directly. Respiratory therapists and exercise physiologists are W-2 employees. Pulmonologists operate through a hybrid model. This ensures consistent, high-quality care.
Quantifiable Results and Cost Savings
Kivo’s virtual program yields impressive results. A peer-reviewed study confirmed significant improvements. Patients saw a 24% improvement in symptoms. Functional capacity improved by 34%. Mood saw a 25% improvement. Program attendance was consistently high, at a median of 83%. These numbers demonstrate strong patient engagement and efficacy.
Beyond clinical outcomes, Kivo offers substantial economic benefits. An independent actuarial analysis estimates significant savings. Kivo’s approach can reduce total healthcare spending by $8,245 per patient annually. This comes from fewer hospitalizations. It includes reduced emergency room visits. Fewer nursing home days also contribute. Preventing a single COPD hospitalization, for instance, saves over $19,000.
Strategic Commercial Expansion
Kivo’s commercial growth strategy leverages diverse channels. It secures robust health plan partnerships. UnitedHealthcare, Humana, Blue Cross, Aetna, Priority Health, Medicare, and Medicaid cover Kivo’s programs. This broad coverage ensures wide patient access.
Strategic health system partnerships also drive growth. Under a fee-for-service model, hospitals refer post-discharge COPD patients. Kivo’s virtual clinic extends health systems' capacity. It helps reduce 30-day COPD readmission penalties. The Hospital Readmissions Reduction Program (HRRP) imposes these penalties. Health systems also capture downstream remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) billing codes.
In parallel, Kivo scales value-based arrangements. It partners directly with Medicare Advantage organizations and accountable care organizations (ACOs). By preventing avoidable events, Kivo generates medical cost offsets. This allows participation in shared savings. It aligns with risk-adjusted capitation benchmarks. This strategy supports long-term financial sustainability and impact.
The Future of Virtual Chronic Disease Management
The new financing will fuel Kivo’s ambitious plans. The company will expand health plan partnerships. Clinical operations will grow nationally. Further advancements to the AI platform are underway. Kivo plans to apply its successful model to other high-cost chronic diseases. These conditions also heavily impact seniors. This expansion promises a future where advanced, accessible virtual care becomes standard. Kivo Health is truly pioneering the next generation of digital health solutions for an aging population.